SCHEMBL6490340

SCHEMBL6490340

CN(C)c1ccc(C2=C(C(=O)Nc3ccc(NCCc4ccccn4)cc3)CCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
MAPK1 P28482 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
MITF O75030 1/20 0.40
TP53 P04637 1/20 0.40
APP P05067 1/20 0.40
HPGD P15428 1/20 0.40
SNCA P37840 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489289 0.90 L3MBTL1 (0.46) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6493547 0.89 L3MBTL1 (0.45) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6490864 0.89 L3MBTL1 (0.45) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6490871 0.89 L3MBTL1 (0.45) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6491912 0.89 RAB9A (0.48) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6503827 0.89 HTT (0.50) RAB9ANPC1MAPTGAASMN1; SMN2
SCHEMBL6501992 0.88 CNR1 (0.54) RAB9ANPC1ALDH1A1GAASMN1; SMN2
SCHEMBL6487298 0.88 L3MBTL1 (0.46) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL6499824 0.87 RAB9A (0.60) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL6487662 0.86 TRPV1 (0.49) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAOA 258/4885MAOB 46/4885RAB9A 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.